Grant: CIHR-ICRH Travel Awards - General pool
Centre hospitalier de l'Université de Montréal (CHUM)
$1,500.00
Canagliflozin Inhibits Hedgehog Interacting Protein (Hhip)-Mediated Renal Tubular Cell Senescence in Type 1 Akita Mice
FY 2023-24
Summary
Sodium-glucose cotransporter 2 (Sglt2) inhibitors are emerging diabetes treatments that were initially designed to target kidney but also found being cardioprotective. We have recently reported that our protein of interest:
hedgehog interacting protein (Hhip) activates Sglt2 expression and promotes kidney aging in diabetic mouse model. In current project, we aim to elucidate the underlying mechanism by giving Sglt2 inhibitor to diabetic mice or specific kidney cell culture under high glucose condition. We have demonstrated that Sglt2 inhibitor is capable of offsetting diabetic kidney injury, possibly, via the inhibition of excessive Hhip carried by extracellular vehicles.
Department
Program
CIHR-ICRH Travel Awards - General pool
Location
Quebec, Canada
Recipient Type
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
495301
Name
Chang Shiao-Ying
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases
Projecttitle
Canagliflozin Inhibits Hedgehog Interacting Protein (Hhip)-Mediated Renal Tubular Cell Senescence in Type 1 Akita Mice
Programtype2
Undefined
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$1,500
Cihrequipment2
$0
Programname2
CIHR-ICRH Travel Awards - General pool
Keyworddelim
Sodium-Glucose Cotransporter 2 (Sglt2) Inhibitors
Abstract
Sodium-glucose cotransporter 2 (Sglt2) inhibitors are emerging diabetes treatments that were initially designed to target kidney but also found being cardioprotective. We have recently reported that our protein of interest:
hedgehog interacting protein (Hhip) activates Sglt2 expression and promotes kidney aging in diabetic mouse model. In current project, we aim to elucidate the underlying mechanism by giving Sglt2 inhibitor to diabetic mice or specific kidney cell culture under high glucose condition. We have demonstrated that Sglt2 inhibitor is capable of offsetting diabetic kidney injury, possibly, via the inhibition of excessive Hhip carried by extracellular vehicles.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chang, Shiao-Ying
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $1,500~ $0~
